Brokers Issue Forecasts for CRBU FY2025 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Caribou Biosciences in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will earn ($1.31) per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

CRBU has been the topic of several other reports. Bank of America lowered their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Finally, Citigroup dropped their target price on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Caribou Biosciences presently has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU opened at $1.52 on Thursday. Caribou Biosciences has a 12-month low of $1.50 and a 12-month high of $8.33. The business’s 50 day moving average is $1.85 and its 200 day moving average is $2.00.

Institutional Investors Weigh In On Caribou Biosciences

Several hedge funds have recently added to or reduced their stakes in CRBU. PFM Health Sciences LP grew its position in Caribou Biosciences by 5.5% during the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after buying an additional 223,299 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Caribou Biosciences by 25.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after buying an additional 536,162 shares in the last quarter. Geode Capital Management LLC grew its stake in Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares during the period. FMR LLC increased its holdings in Caribou Biosciences by 7.4% in the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after acquiring an additional 109,606 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Caribou Biosciences during the second quarter valued at $2,432,000. 77.51% of the stock is owned by hedge funds and other institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.